Chinese sumac (Rhus chinensis Mill.) fruits are traditionally used as a condiment and herb. The aim of this study is to evaluate the preventive effect of the ethanolic extract from Chinese sumac fruits against CCl-induced liver fibrosis in mice and to delineate the underlying mechanisms. The results showed that the ethanolic extract substantially decreased AST, ALT, MDA, and hydroxyprolin (HYP), restored GSH, SOD, and CAT, and prevented liver fibrosis induced by CCl. Further, investigation revealed that the prevention against liver fibrosis may be related to heightened inflammation due to suppression of the release of IL-1β, IL-6, and TNF-α, and the downregulation of COX-2, iNOS, p-NF-κB, and p-P38; the prevention of hepatocyte apoptosis was due to the upregulation of Bcl-2 and downregulation of Bax; the reduction of HSCs activation was due to the downregulation of TGF-β1 and upregulation of PPAR-γ; and the decrease in the extracellular matrix (ECM) deposition was due to the regulation of MMP9 and TIMP2. These findings proved that Chinese sumac fruits could effectively prevent CCl-induced liver fibrosis in mice and may be used to develop functional foods and/or nutraceuticals to prevent or alleviate liver fibrosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/d0fo00548g | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predictive value of neutrophil-to-lymphocyte ratio for long-term adverse outcomes in cirrhosis patients post-transjugular intrahepatic portosystemic shunt.
Sci Rep
January 2025
Department of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, Guangdong, China.
The neutrophil-to-lymphocyte ratio (NLR) may predict outcomes in end-stage liver disease, but its value after transjugular intrahepatic portosystemic shunt (TIPS) is unclear. This study explored the link between NLR and long-term outcomes in decompensated cirrhosis patients post-TIPS. We retrospectively analyzed 184 patients treated between January 2016 and December 2021, noting demographic data, lab results, and follow-up outcomes, including liver transplantation or death.
View Article and Find Full Text PDFMetabolic dysfunction-associated steatotic liver disease increases the risk of primary open-angle glaucoma.
Ophthalmol Glaucoma
January 2025
Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China; NHC Key Laboratory of Myopia and Related Eye Diseases; Key Laboratory of Myopia and Related Eye Diseases, Chinese Academy of Medical Sciences, Shanghai, 200031, China; Shanghai Key Laboratory of Visual Impairment and Restoration, Shanghai, 200031, China; State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai, 200032, China. Electronic address:
Purpose: Liver disease is associated with a range of extrahepatic complications, which have recently been expanded to include ophthalmic conditions. However, evidence is lacking regarding its impact on primary open-angle glaucoma (POAG). This study aimed to investigate whether major liver diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD), alcoholic liver disease (ALD), viral hepatitis, and liver fibrosis and cirrhosis, were associated with POAG.
View Article and Find Full Text PDFEVALUATION OF THE EFFECTS OF FAVIPIRAVIR (T-705) ON THE LUNG TISSUE OF HEALTY RATS: AN EXPERIMENTAL STUDY.
Food Chem Toxicol
January 2025
Department of Histology and Embryology, Erciyes University, Faculty of Medicine, 38039 Kayseri, Turkey. Electronic address:
Favipiravir, a broad-spectrum RNA-dependent RNA polymerase inhibitor widely used during the COVID-19 pandemic, effectively reduces viral load but has been linked to inflammatory changes in tissues such as the liver and kidneys. High-dose and prolonged use of favipiravir for COVID-19 raises concerns about its potential toxic effects on the lungs, particularly in patients with pre-existing pulmonary conditions. This study investigated favipiravir's effects on lung tissue in healthy rats.
View Article and Find Full Text PDFA Guide to Pathophysiology, Signaling Pathways, and Preclinical Models of Liver Fibrosis.
Mol Cell Endocrinol
January 2025
Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY,11439, USA. Electronic address:
Liver fibrosis is potentially a reversible form of liver disease that evolved from the early stage of liver scarring as a consequence of chronic liver injuries. Recurrent injuries in the liver without any appropriate medication cause the injuries to get intense and deeper, which gradually leads to the progression of irreversible cirrhosis or carcinoma. Unfortunately, there are no approved treatment strategies for reversing hepatic fibrosis, making it one of the significant risk factors for developing advanced liver disorders and liver disease-associated mortality.
View Article and Find Full Text PDFStatins and non-alcoholic fatty liver disease: A concise review.
Biomed Pharmacother
January 2025
Laboratory of Clinical and Experimental Physiopathology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, RJ, Brazil.
Non-alcoholic fatty liver disease (NAFLD) is a common hepatic manifestation of metabolic syndrome affecting 20-30 % of the adult population worldwide. This disease, which includes simple steatosis and non-alcoholic steatohepatitis, poses a significant risk for cardiovascular and metabolic diseases. Lifestyle modifications are crucial in the treatment of NAFLD; however, patient adherence remains challenging.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!